Stocks and Investing Stocks and Investing
Tue, November 14, 2023
Mon, November 13, 2023

Nigel Dally Maintained (ARQT) at Buy with Decreased Target to $10 on, Nov 13th, 2023


Published on 2024-10-28 07:33:25 - WOPRAI, Nigel Dally
  Print publication without navigation


Nigel Dally of Morgan Stanley, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Buy with Decreased Target from $45 to $10 on, Nov 13th, 2023.

Nigel has made no other calls on ARQT in the last 4 months.



There are 6 other peers that have a rating on ARQT. Out of the 6 peers that are also analyzing ARQT, 3 agree with Nigel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Sean Kim of "JonesTrading" Downgraded from Strong Buy to Hold on, Wednesday, November 8th, 2023
  • Uy Ear of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Friday, October 27th, 2023
  • Jonathan Block of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $6 on, Friday, October 13th, 2023


These are the ratings of the 3 analyists that currently disagree with Nigel


  • Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $8 on, Monday, November 6th, 2023
  • Louise Chen of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $50 on, Tuesday, August 22nd, 2023
  • Ken Cacciatore of "TD Cowen" Maintained at Buy with Decreased Target to $50 on, Wednesday, August 9th, 2023
Contributing Sources